Home > Journals > Minerva Cardioangiologica > Past Issues > Minerva Cardioangiologica 1999 May;47(5) > Minerva Cardioangiologica 1999 May;47(5):137-44





A Journal on Heart and Vascular Diseases

Official Journal of the Italian Society of Angiology and Vascular Pathology
Indexed/Abstracted in: EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 0,752




Minerva Cardioangiologica 1999 May;47(5):137-44

language: English, Italian

Efficacy evaluation of prostaglandin E1 against placebo in patients with progressive systemic sclerosis and significant Raynaud's phenomenon

Bartolone S., Trifiletti A., De Nuzzo G., Scamardi R., Larosa D., Sottilotta G., Raffa A., Barbera N.


Background. Raynaud's phenomenon, due to connective tissue diseases, is difficult to treat successfully. Symptomatic improvement has been reported using nifedipine or iloprost, but adverse side effects may limit their use. The purpose of this study was to examine the effects of PGE1 (Alprostadil) in patients with scleroderma and severe Raynaud's disease.
Methods. Twelve females, aged 50-67 years, were included in the study with six of them receveing a 3-hour infusion of alprostadil at the standard dosage of 60 microgram in 250 cc of physiological infusion for six consecutive days and the remaining six receiving placebo (250 cc of physiological infusion adminstered in the same manner).
Results. After infusion, blood flow, digitally measured by telethermography was increased only in patients treated with alprostadil. The number, frequency and severity of attacks recorded were reduced only in patients treated with alprostadil. No side effects were recorded during and after the infusion.
Conclusion. In conclusion, alprostadil is effective in the management of Raynaud's phenomenon, due to scleroderma.

top of page

Publication History

Cite this article as

Corresponding author e-mail